Machine-assisted translation — the German original version is authoritative.
Tissue & Regeneration
BPC-157
Body Protection Compound 157 · PL 14736 (verwandt)
BPC-157 is a synthetic peptide derived from a sequence of a protein found in gastric juice. Since the 1990s it has been studied predominantly in animal experiments for tissue regeneration. It is not approved as a medicine for human use in any country; robust human data are largely lacking.
Regulatory status
Not approved for humans
Not approved for human use — human safety not established.
Drug class
Synthetic peptide (experimental, "body protection compound")
Half-life (informative)
Short in plasma; reliable human pharmacokinetic data are largely lacking.
Studied in the literature
In animal studies investigated systemically and locally, among others. No established, approved human use.
Mechanism of action
In preclinical models, effects on angiogenesis (formation of new blood vessels), tendon, muscle and gut healing as well as on various signaling pathways (including VEGF, the NO system) are described. These findings come almost entirely from cell and animal experiments; the mechanism of action in humans is not established.
The frequently cited "oral efficacy" is likewise based on animal models.
Research history
Studied since the 1990s, primarily by research groups around P. Sikirić (Croatia). The body of data is almost entirely preclinical (rodents). Controlled clinical studies in humans that would demonstrate a benefit are largely lacking.
Regulatory status by region
The FDA placed BPC-157 in the 503A compounding process into the category with significant safety concerns ("Category 2"); the regulatory framework is currently being reviewed. Important: even removal from a restriction list would not constitute a marketing authorization and would not be proof of safety.
Not an approved medicine.
BPC-157 is on the prohibited list of the World Anti-Doping Agency (category S0, non-approved substances).
Research areas
- Tendon, ligament and muscle healing (preclinical)
- Gastrointestinal protection/healing (preclinical)
- Angiogenesis (preclinical)
Documented effects (from the literature)
- In animal models, predominantly regenerative effects are reported.
- Robust, documented effects in humans are scarcely available.
Safety concerns & caution
- Human safety has not been systematically investigated — long-term effects unknown.
- Possible effects on the formation of new blood vessels raise theoretical questions (e.g. in the context of tumor biology) that are unresolved.
- No established contraindications, because no approved clinical use exists.
Risks of gray-market purchase
- Widely sold as a "research peptide"; purity, identity and sterility are unassured.
- Impurities from uncontrolled synthesis are a real risk.
- "Anecdotal reports" from forums are not scientific evidence.
Frequently asked questions
Are there human studies on BPC-157?
Very few, and none that demonstrate a clear benefit with an approved safety profile. The evidence is almost entirely from animal experiments.
Why is it so popular then?
Above all through forums, social media and sale as a "research peptide". Popularity is no substitute for clinical evidence and approval.
Is BPC-157 permitted in sport?
No. It is on the WADA prohibited list (S0).
Is the regulatory status of BPC-157 changing in 2026?
The US compounding framework for BPC-157 is under regulatory review. Important: even if the substance were removed from a restriction list, that would not mean a marketing authorization and not proof of safety. BPC-157 remains unapproved, and a 2025 expert review expressly advises against clinical use because robust human data are lacking.
Sources
Primary and reference sources for your own reading.
Related substances
Unfamiliar terms? Look them up in the glossary or read the fundamentals.
This profile is for information and education only. It is not medical advice and deliberately contains no dosing or usage details. Decisions about use belong in a doctor’s hands.